支气管动脉灌注联合口服依托泊苷治疗小细胞肺癌的疗效观察

摘要

OBJECTIVE:To probe into the efficacy of bronchial artery perfusion combined with oral etoposide in treatment of small cell lung cancer .METHODS:116 patients with small cell lung cancer admitted into the Second Affiliated Hospital of Mudanjiang Medical School from Aug .2013 to Oct.2015 were selected to be divide into observation group and control group via the random number table , with 58 cases in each.The control group were treated with bronchial artery perfusion of etoposide combined with cis-platinum, while the observation group additionally received oral etoposide capsules after operation of two day based on the control group .The total effective rate, one-year disease-free survival rate and two-year survival rate were compared between two groups .RESULTS:The total effective rate , one-year disease-free survival rate and two-year survival rate of observation group were respectively 94.83%(55/58), 37.93%(22/58) and 15.51%(9/58), significantly better than that of control group [63.79%(37/58)、8.62%(5/58)、3.45%(2/58)], with statistically significant difference (P<0.05).CONCLUSIONS:The efficacy of bronchial artery perfusion combined with oral etoposide in treatment of small cell lung cancer is significant , which is worthy of the further clinical research .%目的：探讨支气管动脉灌注联合口服依托泊苷治疗小细胞肺癌的疗效。方法：选取2013年8月—2015年10月牡丹江医学院第二附属医院收治的116例小细胞肺癌患者作为研究对象，以随机数字表法分为观察组和对照组各58例。对照组患者单纯采用支气管动脉内灌注依托泊苷联合顺铂治疗；观察组在对照组支气管动脉灌注的方法上术后第2日开始加用依托泊苷胶囊口服。对比2组小细胞肺癌患者的总有效率、1年无病生存率和2年生存率。结果：观察组患者的总有效率为94．83％（55／58）、1年无病生存率为37．93％（22／58）、2年生存率为15．51％（9／58），均明显优于对照组的63．79％（37／58）、8．62％（5／58）、3．45％（2／58），差异有统计学意义（P＜0．05）。结论：支气管动脉灌注联合口服依托泊苷治疗小细胞肺癌，效果显著，值得临床进一步研究。